CYP 2.44% 20.0¢ cynata therapeutics limited

Ann: Cynata to Acquire IP from Tekcyte, page-36

  1. 838 Posts.
    lightbulb Created with Sketch. 340
    Your argument is all over the place. First you are disappointed that we hired someone to chase partners, but at the same time you are disappointed that Killian hasn’t gotten us any partners? You don’t get to eat your cake and have it too. Either you think we’re too far away from partnerships and the guy shouldn’t have been hired, in which case you have no reason to criticise Killian for not having signed a license agreement. Or we’re close and it makes sense to get someone with proven experience on board to secure the best deal/s for Cynata.

    If there is a sniff of a partner on the way for DFU (and we know from the webinar that multiple NDA’s have been signed), then the acquisition DID need to be made prior to that been finalised. I can’t explain it any clearer than this: complexity kills deals. Having ownership of the relevant IP is critical.

 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.